为什么澳大利亚医疗健康并购需要单独看？
澳大利亚医疗健康企业对中国买方有吸引力，尤其是诊所、康复、养老、体检、医疗美容、专科服务和健康消费品牌。但价值高度依赖专业人员、牌照、患者信任和合规。
买方不能只看收入增长。医生留任、隐私、保险、投诉和监管记录都会影响交易价值。
尽调重点
买方应审查牌照、医生合同、患者来源、收入结构、保险、投诉、设备、租赁、员工、隐私合规、税务和诉讼。若目标涉及敏感数据或外资审批，应提前评估FIRB路径。
估值重点
估值应看可持续收入、医生依赖、患者复购、毛利率、设备投资、租赁期限和团队留任。若创始医生高度关键，交易结构应包含留任和递延付款。
交易结构
常见结构包括控股收购、分阶段收购、医生留任、管理层激励和少数股权保留。
Lyndon如何协助
Lyndon可协助中国买方、澳大利亚医疗企业主和顾问进行估值、资料室准备、FIRB路径讨论和交易执行。
About the Author
Daniel Bae
Co-founder & CEO, Lyndon Advisory
Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Lyndon Advisory to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.
About Lyndon Advisory
Lyndon Advisory is an M&A advisory firm built for Asia Pacific. We help business owners sell their companies and investors make strategic acquisitions with senior-led execution, disciplined process management, and AI-supported buyer intelligence.
Learn about selling your business